Money will pour into I health sector. There is money sitting on the sidelines waiting. With ISN having 20 patents and a management most companies die for I think this journey has many greener pastures ahead. That said there is broad scope here for diverse respiratory orders. In other words multiple revenue streams. Expectong 4 to get bitten
